Mon, 16 Dec 2019

MUNICH, GERMANY / ACCESSWIRE / November 28, 2019 / Proteros biostructures GmbH today announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin has been co-founded by Proteros in 2013. Rodin's security holders will receive an upfront payment of $100 million plus milestone payments.

For more information please visit

https://investor.alkermes.com/news-releases/news-release-details/alkermes-completes-acquisition-rodin-therapeutics

https://rodintherapeutics.com/press_releases/alkermes-to-acquire-rodin-therapeutics/

About Proteros biostructures GmbH

Proteros, Martinsried/Munich, Germany is a private biotechnology company aimed at drug discovery for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan in different types of service and collaborative relationships. For more information please visit www.proteros.com

Contact:
Proteros biostructures GmbH
Dr. Torsten Neuefeind, Claire Donat
Email: requests@proteros.com
For Press Enquiries:
MC Services AG
Raimund Gabriel, Andreas Jungfer
Email:Andreas.Jungfer@mc-services.eu
Phone: +49 (0) 89 210228 0

SOURCE: Proteros biostructures GmbH



View source version on accesswire.com:
https://www.accesswire.com/568420/Proteros-co-founder-of-Rodin-Therapeutics-announces-Rodins-acquisition-by-Alkermes

More New York News

Access More

Sign up for New York State News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!